Collagen Mimetic Peptide Devices for Controlled Drug Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing drug delivery systems are inefficient, costly, and often cause unintended side effects due to non-targeted administration, necessitating higher doses and longer treatment periods, while medical devices for healing and recovery lack targeted and controlled delivery mechanisms.

Innovation Solution

Conjugation of therapeutic and diagnostic compounds to collagen mimetic peptides (CMPs) to create targeted drug delivery systems and medical devices that facilitate precise delivery to disease sites, enhancing treatment efficacy and reducing side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional drug delivery systems are used, then drugs can be administered to patients, but the drugs are delivered non-targetedly causing unintended side effects and requiring higher doses

Engineering Contradiction:

Improvetreatment efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by modifying specific regions of the collagen molecule to create targeted delivery. The collagen is engineered with specific amino acid sequences and structural variations that enable it to bind selectively to disease sites while maintaining its natural appearance to the immune system. This localized modification allows the drug delivery system to concentrate therapeutic effect at the target site while minimizing systemic exposure and side effects.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses collagen as an intermediary carrier molecule that bridges the gap between the drug and the target disease site. The collagen mimetic peptides act as mediators that naturally traverse biological barriers and accumulate at sites of tissue repair or disease, thereby delivering the therapeutic payload selectively. This intermediary approach allows non-targeted drugs to be delivered through a targeted vehicle, reducing side effects while maintaining efficacy.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If higher doses are administered to overcome non-targeted delivery, then treatment efficacy may be improved, but treatment costs increase and treatment duration extends

Engineering Contradiction:

Improvetreatment efficacyVSAvoiddrug dose

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent segments the drug delivery function by separating the therapeutic payload from the delivery vehicle. The collagen mimetic peptide serves as a distinct delivery vehicle that can be independently optimized for targeting, while the drug payload is attached or conjugated to it. This segmentation allows the system to achieve targeted delivery at lower overall doses, reducing the quantity of substance required while maintaining treatment efficacy.

Inventive Principle:

Principle #1Segmentation

3Strength

If medical devices are used for healing and recovery, then physical support and protection are provided, but targeted and controlled delivery mechanisms are lacking

Engineering Contradiction:

Improvestructural supportVSAvoidcontrolled delivery

Core Design Contradiction:

StrengthVSEase of operation

Solution Approach 1:

The patent merges the structural support function of medical devices with the targeted delivery capability of biomolecules. Collagen-based materials are integrated into medical devices such as wound dressings, implants, and scaffolds, combining mechanical strength with active drug delivery. The collagen component provides both structural integrity and the ability to deliver therapeutic agents in a controlled manner, thereby merging these previously separate functions into a single integrated system.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent introduces dynamics into medical devices by incorporating collagen mimetic peptides that can actively respond to biological signals and change their behavior in response to the healing environment. These dynamic components can adjust drug release rates, migrate toward injury sites, or change conformation in response to pH or enzymatic cues, thereby providing controlled delivery that adapts to the patient's needs rather than relying on passive, static device structures.

Inventive Principle:

Principle #15Dynamics

Data Source

PatentUS12419936B2Collagen peptide-based medicament compositions and devices and methods of production and use thereof

Publication Date: 2025.09.23 SUSTAIN HLDG LLC

AI summary

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including anterior and posterior segment ocular diseases or disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases or disorders.